



29th International Conference *Cardiology Today*

Cardiovascular Death,
Prevention Strategies 2024

6-7 April 2024
Hilton Nicosia



Program

Under the auspices of:





CRE/01/CV/02-2024



Welcome Message from Conference Chair

Dear colleagues,

On behalf of the Organizing Committee of the Cyprus Society of Cardiology, we would like to invite you to the 29th International Conference 'Cardiology Today' which is going to take place on 6 – 7 of April 2024, at the Hilton Nicosia Hotel.

Participants will have the opportunity to exchange ideas in emerging subjects from different fields of cardiology practice, challenging the cardiologist of the 21st century to the mission of reducing the burden of cardiac diseases.

The two-day Conference will include lecturers, round table discussions and satellite symposia. Participants will have the opportunity to join sessions with world class experts and doctors of the field.

This year's Conference will include the latest developments in the fields of arrhythmias, cardiac surgery, invasive cardiology, prevention, cardiomyopathies and imaging. It will also focus on the prevention of the cardiac death, the leading cause of morbidity and mortality globally.

We look forward to welcoming you to Cyprus, where you will enjoy the famous Cyprus hospitality and discover the beauty of the island of Aphrodite.

Thank you,

Hera Heracleous
President of the Cyprus Society of Cardiology

Organising Committee

Hera Heracleous – President

Elias Papasavvas – Vice President

Georgia Daniel – Secretary

Maria Karakyriou – Secretary Assistant

Evagoras Economides – Treasurer

Joseph Moutiris – Member

Ioannis Stefanou – Member

Vicky Zenios – Member

Theodoros Christodoulides – Past President

SiderAL[®]

Μοναδική σουκροσωμική τεχνολογία

ΜΕΤΑ**Fe**ΡΕΙ... ΕΞΥΠΝΑ



SiderAL[®]
FORTE

SiderAL[®]
FOLICO

SiderAL[®]
DROPS INT.

SiderAL[®]
SPORT

SID/03/CY/01-2023

WinMedica
Serving Health for Life

Προϊόν έρευνας ••• | PharmaNutra Italy

Τα συμπληρώματα διατροφής δεν πρέπει να χρησιμοποιούνται ως υποκατάστατο μίας ισορροπημένης διαίτας. Το προϊόν αυτό δεν προορίζεται για την πρόληψη, αγωγή ή θεραπεία ανθρώπινης νόσου. Συμβουλευτείτε τον γιατρό σας εάν είστε έγκυος, θηλάζετε, βρίσκεστε υπό φαρμακευτική αγωγή ή αντιμετωπίζετε προβλήματα υγείας. Να φυλάσσεται μακριά από τα μικρά παιδιά. Μην υπερβείτε την ημερήσια συνιστώμενη δόση. Μπορείτε να βρείτε περισσότερες πληροφορίες στο ΦΟΧ του προϊόντος στην ιστοσελίδα www.papaloizou.com

Papaloizou

Χρ.Γ. Παπαλοΐζου Λτδ
Λεωφ. Κιλκίς 35, 2234 Λατοιά
www.papaloizou.com



Speakers

Oren Carspi, MD PhD

Director of Heart Failure Unit and the Cardiovascular Research and Innovation Center, Cardiology Head of The Laboratory for Cardiovascular Precision Medicine, Faculty of Medicine

Christos Eftychiou, MD, PhD, FESC

Interventional Cardiologist, Assistant Director of Cardiology Department, Nicosia General Hospital

Nicos Eteokleous

Interventional Cardiologist
Cardiology Department, Nicosia General Hospital

Georgios M. Georgiou, MD, MSc (Health informatics & Telemedicine), FESC, FACC, FSCAI,

Clinical Associate Professor, Medical School, European University of Cyprus
Interventional Cardiologist, past president of the Cyprus Society of Cardiology Director, Cardiology Department, Apollonion Private Hospital, Nicosia, Cyprus

Tim Meyer, MD, PhD

Saarland University, Germany

Antonios Pantazis

Consultant Cardiologist
Chair of the Inherited Cardiovascular Conditions services at The Royal Brompton and Harefield Hospitals, part of Guy's and St Thomas' NHS Foundation Trust.
Head of the Echocardiography Department at NIMH, Past chairman of the ESC WG on Myocardial and Pericardial Diseases.
Sydney Street
London, UK

Antonio Pelliccia

Institute of Sport Medicine and Science,
Italian National Olympic Committee, Rome, Italy

Marios Petrou, PhD FRCS

Clinical Director for Cardiovascular Services,
Royal Brompton Hospital
Heart, Lung and Critical Care Clinical Group,
Guy's and St Thomas's NHS Foundation
Trust Ivo Planinc

Ivo Planinc, MD, PhD

Division for Intensive Cardiac Care,
Heart Transplantation and Arrhythmias
Department of Cardiovascular Diseases,
University Hospital Centre Zagreb

Ioannis Tzanavaros

Clinical Professor at the University of Nicosia Medical School

Anastasia Vamvakidou, MBBS, MRCP, MSc

Consultant Cardiologist, Royal Brompton Hospital
Part of Guy's and St Thomas' NHS Foundation Trust

Panos E. Vardas

Emeritus Professor of Cardiology, University of Crete
Heart Sector, Hygeia Hospitals Group
President of ESC (2012-2014)
Deputy Editor European Heart Journal – Digital Health and Innovation

Vassilios Vassiliou

Professor of Cardiology, University of East Anglia,
Norwich, UK
Consultant Cardiologist, Norfolk and Norwich University Hospital and Royal Brompton Hospital, London
Treasurer, European Association of Preventive Cardiology
Council Member, British Heart Valve Society

Hussain Wajid

Consultant Cardiologist, Cardiac Electrophysiologist,
Heart Rhythm Centre, Harefield Hospital
Chief Clinical Information Officer, Royal Brompton and Harefield Hospitals part of Guys and St Thomas' NHS Foundation Trust

Robert G Xuereb

MD FRCP(L) FRCP(E) FESC FACC FHFA MOM
Consultant Cardiologist
Past Chairman Department of Cardiology Mater Dei Hospital
Malta 2014-2024
Past President Maltese Cardiac Society 2013-2023

Chairs & Moderators

Petros Agathangelou

Consultant Cardiologist & Consultant Physician,
President of the Cyprus Medical Association

Loizos Antoniadis, MD, PhD, FESC, FACC

Cardiologist

Panayiotis Avraamides

Consultant Cardiologist & Consultant Physician,
President of the Cyprus Medical Association

Vasilis Barberis

Cardiologist - Private Practice, Nicosia, Cyprus Chair,
Cyprus Heart Failure WG, Cyprus

Theodoros Christodoulides

Cardiologist - DAS Heart Failure (University
of Zurich) Board Member (Past President),
Cyprus Society of Cardiology

Evie Christodoulou

Savvas Constantinides

Georgia Daniel

Evagoras Economides, MA(Cantab), BM BCh(Oxon), FACC

Clinical Associate Professor of Medicine,
University of Nicosia Medical School

Christos Eftychiou

Georgios M. Georgiou

Clinical Associate Professor, Medical School,
European University of Cyprus Interventional
Cardiologist, past president of the Cyprus Society
of Cardiology Director, Department of Interventional
Cardiology Apollonio Private Hospital, Nicosia, Cyprus

Georgios P. Georgiou

Cardiothoracic Surgeon, Aretaeio Hospital - Assistant
Professor, School of Medicine UC - Visiting Senior
Lecturer of Surgery, Sackler Faculty of Medicine,
Tel Aviv University - Chairman WG of Cardiac Surgery,
Cyprus Society of Cardiology

Marios Ioannides

Giorgos Kanelopoulos

Cardiologist, Aretaeio Hospital, Nicosia, Cyprus

Themis Komodromos

American Board Certified Cardiovascular
and Interventional Cardiologist Specialist

Pantelis Kourtellaris

Cardiologist and Electrophysiologist,
American Medical Center, Nicosia - Cyprus

Petros Mavrommatis

Cardiac Care Centre, Paphos, Cyprus

Theodoros Ntoskas

Consultant Cardiologist Directro, Department
of Cardiology, Nicosia General Hospital

Y. Panagiotides

Ilias.Papasavvas

Cardiologist, Electrophysiologist

Kyriakos Yiangou

Cardiologist, Past President, Cyprus Society
of Cardiology, EACVI accreditation in adult
transthoracic echocardiography,
MSc in Sports Cardiology (London)



Satellite Symposium Speakers

Christodoulos Papadopoulos, MD, PhD, FESC

Associate Professor of Cardiology, 3rd Cardiology Clinic,
Hippokrateio University Hospital,
Medical School Aristotle University of Thessaloniki

Theodoros Christodoulides MD, MA, FESC

DAS Cardiologist

Michalis S. Neofytou, MD

Interventional Cardiologist

Alexia Stavradi

NHS Director- Greece, Heart Failure Unit, Cardiology Department,
General Hospital G. Papanikolaou, Thessaloniki, Greece
President of the Heart Failure Working Group,
Hellenic Cardiological Society

Haralampos Milionis

Professor of Internal Medicine, School Of Medicine,
University of Ioannina

Dimitrios Chatzis

Cardiologist - Visiting Assistant Professor in Cardiology
at European University Cyprus

Despina Parcharidou

Cardiology registrar, Cardiology Clinic,
AHEPA University Hospital, Thessaloniki, Greece

UNITED FOR LONG-LASTING[†] LDL-C CONTROL¹

LEQVIO is administered every 6 months* and provides effective LDL-C control, supported by 6+ years of data^{1,2}

*Two doses a year after the two initial doses. Single subcutaneous injection at the start of treatment, again at 3 months, and thereafter every 6 months.¹

[†]LDL-C reduction was maintained during each 6-month dosing interval after 2 initial doses of inclisiran.

 **LEQVIO**[®]
inclisiran

▼ **LEQVIO™ Important note: Before prescribing, consult full prescribing information.** **Presentation:** Solution for injection: Each pre-filled syringe contains inclisiran sodium equivalent to 284 mg inclisiran in 1.5 ml solution. **Indications:** Indicated in adults with primary hypercholesterolaemia (heterozygous familial and nonfamilial) or mixed dyslipidaemia, as an adjunct to diet: • in combination with a statin or statin with other lipidlowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or • alone or in combination with other lipidlowering therapies in patients who are statinintolerant, or for whom a statin is contraindicated. **Dosage and administration:** Recommended dose: 284 mg administered as a single subcutaneous injection: initially, again at 3 months, followed by every 6 months. **Missed dose:** • If a planned dose is missed by less than 3 months, inclisiran should be administered and dosing continued according to the patient's original schedule. • If a planned dose is missed by more than 3 months, a new dosing schedule should be started – inclisiran should be administered initially, again at 3 months, followed by every 6 months. **Treatment Transition from PCSK9 Inhibitor:** Inclisiran can be administered immediately after the last dose of a monoclonal antibody PCSK9 inhibitor. To maintain LDL-C lowering, it is recommended that inclisiran is administered within 2 weeks after the last dose of a monoclonal antibody PCSK9 inhibitor. **Special populations:**

Renal impairment: No dose adjustment is necessary for patients with renal impairment (mild, moderate or severe), or end-stage renal disease. **Hepatic impairment:** No dose adjustment is necessary for patients with mild or moderate hepatic impairment. Inclisiran should be used with caution in patients with severe hepatic impairment. **Pediatric patients (below 18 years):** The safety and efficacy of inclisiran have not been established. **Geriatric patients (65 years of age or above):** No dose adjustment is necessary. **Method of administration:** Intended for administration by a healthcare professional. For subcutaneous injection into the abdomen. Leqvio should be inspected visually for particulate matter prior to administration. Each pre-filled syringe is for single use only. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. **Warnings and precautions:** **Hemodialysis:** Hemodialysis should not be performed for at least 72 hours after inclisiran dosing. **Pregnancy, lactation, fertility** **Pregnancy:** No available human data. Animal reproduction studies have not shown risk of increased fetal abnormalities. **Lactation:** Not known if transferred into human milk. A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from inclisiran therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman. **Fertility:** No human data. No effects on animal fertility. **Adverse drug reactions:** **Common** ($\geq 1/100$ to $< 1/10$): Adverse events at the injection site

(includes injection site reaction, injection site pain, injection site erythema, and injection site rash). **Interactions:** Not a substrate, inhibitor or inducer of CYP450 enzymes or common drug transporters. Not expected to have clinically significant interactions with other medications. Based on the limited data available, clinically meaningful interactions with atorvastatin, rosuvastatin or other statins are not expected. **Packs and prices:** LEQVIO solution for injection 284mg/1.5ml in pre-filled syringe: €2408.73, LEQVIO solution for injection 284mg/1.5ml in pre-filled syringe (with needle guard): €2393.01.

LEQ01/2021

Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to: Novartis Pharma Services Inc., Methonis Tower, 73 Makarios Avenue, 1070 Nicosia, Tel: +357 22 690 690 (Pharmacovigilance Department), Fax: +357 22 315032 or to Pharmaceutical Services, Ministry of Health, CY-1475, www.moh.gov.cy/phs, Tel: +357 22 608 632/661, Fax: +357 22 608 649, by completing the Yellow Card which is available to the public pharmacies or electronically in the website www.kitrinikarta.gov.cy.

References: 1. Leqvio Summary of product characteristics. Novartis. August 2022. 2. RS Wright, FJ Raal, W Koenig, U Landmesser, LA Leiter, GG Schwartz, A Lesogor, P Maheux, Z Tallozy, S Vikarunnessa, X Zang, KK Ray. ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients. Data presented at the ESC Congress on August 28, 2023.

 **NOVARTIS**

Novartis Pharma Services Inc.

Methonis Tower, 73 Makarios Avenue, 1070 Nicosia, Tel: +357 22 690 690, Fax: +357 22 496 798



Program

SATURDAY 06 APRIL 2024

08:30 – 09:00	Registrations
09:00 - 10:15	<p>Heart Failure – Can we do better? Chairs: T. Christodoulides, V. Barberis Moderators: K. Yiangou, Y.Panagiotides</p>
09:00 – 09:20	<p>Chemotherapy induced cardiomyopathy: diagnosis and management Oren Caspi</p>
09:20 – 09:40	<p>Advanced heart failure therapy- The best time to consider the next step Ivo Planinc</p>
09:40 – 10:00	<p>Personalized medicine in diuretic therapy Oren Caspi</p>
10:00 – 10:15	Discussion
10:30 – 10:45	<p>Satellite Symposium From innovation to standard clinical practice. SGLT2 inhibitors in heart or renal failure. Christodoulos Papadopoulos</p> 
10:45 – 11:15	Opening of the Exhibition and Coffee Break
11:15 – 11:45	<p>Satellite Symposium Leqvio: New advances in treating Hypercholesterolaemia - From clinical trials to daily practice. Theodoros Christodoulides, Michalis S. Neofytou</p> 
11:45 - 13:20	<p>Arrhythmias - The challenge to recognize the threat Chairs: P. Agathangelou, P. Kourtellaris Moderators: E.Papasavvas, T. Ntoskas</p>
11:45 – 12:05	<p>Novel tools and technologies in AF Ablation – Are we really getting better? Hussain Wajid</p>
12:05 – 12:25	<p>How mitral valve pathology can increase the risk of sudden cardiac death Anastasia Vamvakidou</p>
12:25 - 12:45	<p>How to manage ventricular arrhythmias in athletes Antonio Pelliccia</p>
12:45 - 13:05	<p>DCM, The role of Imaging in risk stratification. Vassilios Vassiliou</p>
13:05 - 13:20	Discussion



13:20 - 13:50	Satellite Symposium Heart failure and SGLT2is: redefining the therapeutic approach regardless of the ejection fraction Alexia Stavрати	
13:50 - 15:00	Lunch	
15:00 - 16:15	Mitral Valve and tricuspid interventions Chairs: P. Georgiou, P. Avramides Moderators: E.Economides, G. Kanelopoulos	
15:00 - 15:20	Transcatheter procedures in mitral valve regurgitation Christos Eftychiou	
15:20 - 15:40	The role of open-heart surgery in mitral valve regurgitation Mario Petrou	
15:40 - 16:00	Symptomatic severe TR: when should we intervene? Anastasia Vamvakidou	
16:00 - 16:15	Discussion	
16:00 - 16:20	UEFA Lecture - Online Chairs: P. Agathangelou, C. Christou Football's Efforts to prevent SCDs Tim Meyer	
16:20 - 16:50	Satellite Symposium Chairs: Dr. Phivos Symeonidis Evolocumab: Cardiovascular risk reduction data in patients with established atherosclerotic cardiovascular disease Haralampos Milionis	
16:50 - 17:20	Coffee Break	
17:20 - 17:50	Satellite Symposium Chairs: Dr. Hera Heracleous The individualized therapeutic approach as the cornerstone of CCS management. The key to an optimal antianginal treatment Chatzis Dimitrios	
17:50 - 19:25	Valvular Heart Disease: In memory of Dr Alain Cribier Chairs: S. Constantinides Moderators: C. Eftychiou, T. Komodromos	
17:50 - 18:10	The Role of the Ross Procedure in the Adult Population Mario Petrou	

18:10 - 18:30	Debate: Severe Aortic Stenosis in a 70-year-old, low- risk patient What is the best approach?
18:30 - 18:50	Surgical treatment offers the best outcomes Ioannis Tzanavaros
18:50 - 19:20	Transcatheter intervention is the optimal solution Giorgos Georgiou
19:10 - 19:25	Discussion
19:20 - 20:25	OPENING CEREMONY
	Keynote Lecture: Cardiology at the dawn of the metaclinical medicine Panos E. Vardas
20:30	GALA DINNER



SUNDAY 07 APRIL 2024

09:00 - 09:30 Registrations

09:30 - 10:45 **Cardiomyopathies**

Chairs: L. Antoniadis, P. Mavrommates

Moderators: M. Ioannides, G. Daniel

09:30 - 09:50 **New treatments in Hypertrophic cardiomyopathy**

Antonis Pantazis

09:50 - 10:10 **Risk stratification in athletes with clinical, and genotype positive-phenotype negative Hypertrophic Cardiomyopathy**

Antonio Pelliccia

10:10 - 10:30 **New concepts in the diagnosis and management of cardiomyopathies. A critical review of the Guidelines**

Antonis Pantazis

10:30 - 10:45 **Discussion**

10:45 - 11:15 **Satellite Symposium**

Chairs: Dr. Maria Karakyriou and Dr. Hera Heracleous

Diagnostic challenges and current therapeutic approach for Transthyretin Cardiac Amyloidosis (ATTR-CM)

Despina Parcharidou



11:15 - 11:45 Coffee Break

11:45 - 13:00 **Interventional Cardiology**

Chairs: G. M. Georgiou, T. Komodromos

Moderators: E.Christodoulou, S.Constantinides

11:45 - 12:05 **Do interventions prevent outcomes?**

Robert G Xuereb

12:05 - 12:25 **Assessment of arrhythmogenic risk in coronary artery disease**

Vassilios Vassiliou

12:25 - 12:45 **The role of Coronary Sinus Reducer in patients with refractory angina**

Nicos Eteokleous

12:45 - 13:00 **Discussion**

Closing Remarks

AVEIR™ VR

Leadless Pacemaker

SETTING THE PACE FOR WHAT'S TO COME.



LONG-TERM
RETRIEVAL.



LONG LASTING.¹



MAPPING PRIOR
TO FIXATION.



Reference

1. AVEIR™ VR Leadless Pacemaker and Delivery Catheter IFU. ARTEN600175956

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

Abbott

The Corporate Village, Da Vincilaan 11 Box F1, 1935 Zaventem, Belgium, Tel: +32 2 774 68 11
cardiovascular.abbott

[™] Indicates a trademark of the Abbott group of companies.

© 2024 Abbott. All Rights Reserved.

MAT-2402257 v1.0 | Item approved for use in Cyprus.



Abbott

distributed by:



phone: +35725040500
email: info@esvascular.com
www.esvascular.com

Cardiovascular Death,
Prevention Strategies 2024

6-7 April 2024 | Hilton Nicosia



15



**Πρόγραμμα
Νοσηλευτικής
Ημερίδας**

Πρόγραμμα Νοσηλευτικής Ημερίδας

08:30 - 09:00	Εγγραφές
09:00 - 09:15	Προσφώνηση από την Πρόεδρο της ΟΕ Καρδιολογικής Νοσηλευτικής Δρ. Μάρθα Κυριάκου Προσφώνηση από την Πρόεδρο της Καρδιολογικής Εταιρείας Δρ. Ήρα Ηρακλέους
Α' Στοργγυλό τραπέζι Καρδιολογική Νοσηλευτική- Κλινική Πρακτική: παρεμβάσεις και διαχείριση Προεδρείο: Δρ. Α. Πρωτοπαπάς, Δρ. Δ. Πατέστος	
09:15 - 09:35	Πνευμονική Εμβολή- Κατευθυντήριες Οδηγίες Π. Κώστα
09:35 - 09:55	Κλινική περίπτωση Γιγαντιαίου (giant) Ανευρύσματος Δεξιάς Στεφανιαίας Αρτηρίας με Αρτηριοφλεβική επικοινωνία στον Στεφανιαίο Κόλπο Λ. Πάρη, Δρ. Μ. Σωτηρίου, Δρ. Λ. Μίσελος, Δρ. Αικ. Λαμπρινού
09:55 - 10:15	Ήρεμη Νύχτα στη Μονάδα Εντατικής Θεραπείας: Ένα Περιστατικό Πολύμορφης Κοιλιακής Ταχυκαρδίας σε Ασθενή με Συγκοπή Ν. Σάββα
10:15 - 10:35	Αξιολόγηση χοροθεραπείας σε ασθενείς με Καρδιακή Ανεπάρκεια Μαριάμ Μχιταριάν
10:35 - 10:45	Συζήτηση
10:45 - 11:15	Διάλειμμα
Β' Στοργγυλό τραπέζι Καρδιολογική Νοσηλευτική: Εξελίξεις και Προοπτική Προεδρείο: Δρ. Μ. Κυριάκου, Α. Μαλακού	
11:15 - 11:55	Active involvement of nurses in the Association of Cardiovascular Nursing and Allied professions (ACNAP) - Development and opportunities Dr. L. Klompstra, President Elect of ACNAP
11:55 - 12:05	Ερευνητικές εξελίξεις στην Κύπρο- Συμμετοχή στο Ευρωπαϊκά δρώμενα Δρ. Μ. Κυριάκου



12:05 - 12:25	Ο ρόλος της φλεγμονής στα οξεία στεφανιαία σύνδρομα: Ο σχεδιασμός της πολυκεντρικής μελέτης κούρτης INFINITY Δρ. Α. Μήτσος, Μ. Δρακομαθιουλάκης, Δρ. Μ. Κυριάκου, Δρ. Σ. Σωκράτους, Δρ. Γ. Καρμιώτη, Δρ. Μ. Μυριανθεούς, Δρ. Α. Ζιάκας, Δρ. Σ. Τζίκας, Δρ. Γ. Κασίμης
12:25 - 12:45	Παράγοντες που επηρεάζουν την ποιότητα ζωής που σχετίζεται με την υγεία μετά από παράκαμψη στεφανιαίας αρτηρίας Θ. Γιωργαλλά, Δρ. Ν. Μίτλεπτον, Δρ. Αικ. Λαμπρινού
12:45 - 13:05	Η αποτελεσματικότητα προγράμματος υποστηρικτικής φροντίδας στους φροντιστές των ασθενών με Καρδιακή Ανεπάρκεια Ν. Βουρή, Δρ. Μ Κυριάκου, Κ. Χατζηγιασεμή, Α. Μαλακτού, Δρ.Κ. Φιλίππου Δρ. Π. Σουρτζή, Δρ. Αικ. Λαμπρινού
13:05 - 13:20	Ο Ψηφιακός Μετασχηματισμός και η Επιστήμη της Αναζωογόνησης: Μερικά στοιχεία από την εμπειρία του Κυπριακού Συμβουλίου Αναζωογόνησης Μ. Δρακομαθιουλάκης
13:20 - 13:30	Συζήτηση
13:30 - 14:30	Γεύμα
Γ' Στοργγυλό τραπέζι Παρεμβάσεις διαχείρισης σε Οξεία και Χρόνια Καρδιακή Ανεπάρκεια Προεδρείο: Δρ. Β. Μπαρμπέρης, Ν. Βουρή	
14:30 - 14:50	Η οξεία Καρδιακή Ανεπάρκεια στα επείγοντα Δρ. Α. Πρωτοπαπάς
14:50 - 15:10	Πρόγραμμα υποστηρικτικής φροντίδας σε ασθενείς με καρδιακή ανεπάρκεια και σακχαρώδη διαβήτη Δρ. Κ. Φιλίππου, Δρ.Μ Κυριάκου, Ν.Βουρή, Α. Μαλακτού, Α. Σαμάρα, Δρ. Ν. Μίτλεπτον, Δρ. Α. Χαραλάμπους, Δρ. Β.Ραφτόπουλος, Δρ. Αικ. Λαμπρινού
15:10-15:30	Φυσική Δραστηριότητα σε ασθενείς με Καρδιακή Ανεπάρκεια Α. Μαλακτού
15:30 - 15:45	Συζήτηση Βραβεύσεις προφορικών ανακοινώσεων

5 ώρες συνεχιζόμενης Επαγγελματικής Εκπαίδευσης

Εγγραφές: Χωρίς Κόστος

Προεγγραφές στον πιο κάτω σύνδεσμο

<https://www.eventora.com/en/Events/29th-international-conference->



FER/SPEC-IMIN/ADV/12-2022



ferinject[®]
ferric carboxymaltose

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε:
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ: Ferinject 50 mg σιδήρου ανά ml ενέσιμο διάλυμα/διάλυμα για έγχυση. **ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Ένα ml διαλύματος περιέχει ένωση καρβοξυμαλτόζης με σίδηρο που αντιστοιχεί σε 50 mg σιδήρου. Κάθε φιαλίδιο των 10 ml περιέχει ένωση καρβοξυμαλτόζης με σίδηρο που αντιστοιχεί σε 500 mg σιδήρου.

ΚΑΤΟΧΟΣ ΤΗΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ: Vifor France 100-101 Terrasse Boieldieu, Tour Franklin La Défense 8, 92042 Paris La Défense Cedex, Γαλλία.

Περαιτέρω πληροφορίες διατίθενται από την GENESIS Pharma (Cyprus) Ltd



Consulco Building, Οδός Μετοχίου 73,
3ος όροφος, 2407, Έγκωμη, Λευκωσία-Κύπρος
Τηλ: +357 22765735, Φαξ: +357 22765736
e-mail: info-cyprus@genesispharmagroup.com
www.genesispharmagroup.com

CSL Vifor



Sponsors





PMI SCIENCE
PHILIP MORRIS INTERNATIONAL

Δημιουργούμε ένα μέλλον απαλλαγμένο από το τσιγάρο

Αναπτύσσουμε εναλλακτικά προϊόντα
χωρίς καύση και αξιολογούμε
τις επιπτώσεις τους στην ατομική
και τη δημόσια υγεία χρησιμοποιώντας
αυστηρές επιστημονικές μεθόδους

Γνωρίστε το PMI Science
pmiscience.com

PMI Science

@pmiscience



*Το παρόν απευθύνεται μόνο σε επιστήμονες
και επαγγελματίες στον τομέα της υγείας*

ΔΕΙΤΕ ΟΛΑ ΤΑ ΔΕΔΟΜΕΝΑ ΜΑΣ

10 & 20 mg
ZANEDIP[®]
lercanidipine hydrochloride

10mg/10mg & 20mg/10mg

Zaneril
Enalapril maleate
Lercanidipine hydrochloride

BETALOC[®] ZOK
 β_1 metoprolol succinate

Logimax[®]
felodipine 5mg / metoprolol succinate ER 50mg

Πριν τη συνταγογράφηση συμβουλευθείτε τις
Περιλήψεις Χαρακτηριστικών των Προϊόντων που
διατίθενται στην ιστοσελίδα www.papaloizou.com

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για **ΟΛΑ**
τα φάρμακα συμπληρώνοντας την «**ΚΙΤΡΙΝΗ ΚΑΡΤΑ**»



Jardiance®

(εμπαγλιφλοζίνη)

PC-GR-102202-Εμπρ-03-2024

Για τις εγκεκριμένες ενδείξεις, τις ανεπιθύμητες ενέργειες, τις προειδοποιήσεις, τις αντενδείξεις, την δοσολογία και λοιπές ουσιώδεις πληροφορίες παρακαλούμε ανατρέξτε στην Περίληψη Χαρακτηριστικών του Προϊόντος

ΚΑΤΟΧΟΣ ΤΗΣ ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ: Boehringer Ingelheim International GmbH, Binger Str. 173, D-55216 Ingelheim am Rhein, Γερμανία. **ΑΡΙΘΜΟΣ(ΟΙ) ΑΔΕΙΑΣ ΚΥΚΛΟΦΟΡΙΑΣ:** Jardiance 10 mg επικαλυμμένα με λεπτό υμένιο δισκία: EU/1/14/930/010-018. Jardiance® 25 mg επικαλυμμένα με λεπτό υμένιο δισκία: EU/1/14/930/001-009. **ΗΜΕΡ/ΝΙΑ ΠΡΩΤΗΣ ΕΓΚΡΙΣΗΣ:** 22 Μαΐου 2014, **ΗΜΕΡ/ΝΙΑ ΑΝΑΝΕΩΣΗΣ ΤΗΣ ΑΔΕΙΑΣ:** 14 Φεβρουαρίου 2019. **ΗΜΕΡΟΜΗΝΙΑ ΑΝΑΘΕΩΡΗΣΗΣ ΤΟΥ ΚΕΙΜΕΝΟΥ:** 24 Ιουλίου 2023. **ΤΙΜΕΣ:** Τιμές Ελλάδας: Jardiance® 10 mg επικαλυμμένα με λεπτό υμένιο δισκία: Χ.Τ.: 34,97€, Ν.Τ.: 30,43€, Λ.Τ.: 48,19€. Jardiance® 25 mg επικαλυμμένα με λεπτό υμένιο δισκία: Χ.Τ.: 34,97€, Ν.Τ.: 30,43€, Λ.Τ.: 48,19€. Τιμές Κύπρου: Jardiance® 10 mg επικαλυμμένα με λεπτό υμένιο δισκία: Λ.Τ. (ΜΕΓΙΣΤΗ ΔΥΝΑΤΗ): 55,08€. Jardiance® 25 mg επικαλυμμένα με λεπτό υμένιο δισκία: Λ.Τ. (ΜΕΓΙΣΤΗ ΔΥΝΑΤΗ): 55,40€. **ΧΟΡΗΓΕΙΤΑΙ ΜΕ ΙΑΤΡΙΚΗ ΣΥΝΤΑΓΗ.**

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και

Αναφέρετε ΌΛΕΣ τις ανεπιθύμητες ενέργειες για ΌΛΑ τα φάρμακα

Συμπληρώνοντας την

“ΚΙΤΡΙΝΗ ΚΑΡΤΑ”



Boehringer Ingelheim Ελλάς Μονοπρόσωπη Α.Ε., Λεωφ. Ανδρέα Συγγρού 340, 17673, Καλλιθέα. Τηλ.: 210 89 06 300.
Γραφείο Μακεδονίας - Θράκης: Αντώνη Τρίτση 15-17 & Μαρίας Κάλλας 6, Πυλαία, 570 01 Θεσσαλονίκη. Τηλ.: 2310 424 618.
E-mail: info@ath.boehringer-ingelheim.com

Τοπικός Αντιπρόσωπος του Κ.Α.Κ. στην Κύπρο: CPO Ltd, Βασ. Παύλου Α' 11, 1096 Λευκωσία, Κύπρος. Τηλ.: +357 22 863 100.